- Home
- BRLT vs SNTI Comparison
BRLT vs SNTI Comparison
Compare BRLT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- SNTI
- Stock Information
- Founded
- BRLT 2005
- SNTI 2016
- Country
- BRLT United States
- SNTI United States
- Employees
- BRLT N/A
- SNTI N/A
- Industry
- BRLT Consumer Specialties
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- SNTI Health Care
- Exchange
- BRLT Nasdaq
- SNTI Nasdaq
- Market Cap
- BRLT 22.6M
- SNTI 21.3M
- IPO Year
- BRLT 2021
- SNTI N/A
- Fundamental
- Price
- BRLT $1.37
- SNTI $3.96
- Analyst Decision
- BRLT Hold
- SNTI Strong Buy
- Analyst Count
- BRLT 5
- SNTI 1
- Target Price
- BRLT $2.40
- SNTI $12.00
- AVG Volume (30 Days)
- BRLT 95.6K
- SNTI 30.3K
- Earning Date
- BRLT 03-12-2025
- SNTI 03-20-2025
- Dividend Yield
- BRLT N/A
- SNTI N/A
- EPS Growth
- BRLT N/A
- SNTI N/A
- EPS
- BRLT 0.03
- SNTI N/A
- Revenue
- BRLT $426,982,000.00
- SNTI N/A
- Revenue This Year
- BRLT N/A
- SNTI $11.52
- Revenue Next Year
- BRLT $1.04
- SNTI $78.57
- P/E Ratio
- BRLT $49.86
- SNTI N/A
- Revenue Growth
- BRLT N/A
- SNTI N/A
- 52 Week Low
- BRLT $1.25
- SNTI $1.52
- 52 Week High
- BRLT $3.21
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- BRLT 31.80
- SNTI 45.36
- Support Level
- BRLT $1.25
- SNTI $3.92
- Resistance Level
- BRLT $1.75
- SNTI $4.50
- Average True Range (ATR)
- BRLT 0.12
- SNTI 0.26
- MACD
- BRLT -0.03
- SNTI -0.03
- Stochastic Oscillator
- BRLT 21.82
- SNTI 20.59
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.